Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
出版年份 2020 全文链接
标题
Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
作者
关键词
-
出版物
BMC CANCER
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-10-16
DOI
10.1186/s12885-020-07516-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients
- (2019) Beili Wang et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer
- (2019) Erik J. van Helden et al. Molecular Oncology
- Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat?
- (2019) Myrto Kastrisiou et al. Cancers
- RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
- (2018) J B Bachet et al. ANNALS OF ONCOLOGY
- Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma
- (2018) C. B. Thomsen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
- (2018) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- The feasibility of using mutation detection in ctDNA to assess tumor dynamics
- (2017) Xin Yi et al. INTERNATIONAL JOURNAL OF CANCER
- Blood-based detection ofRASmutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-basedRAStesting
- (2017) Wolff Schmiegel et al. Molecular Oncology
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015
- (2017) et al. JAMA Oncology
- Integrated digital error suppression for improved detection of circulating tumor DNA
- (2016) Aaron M Newman et al. NATURE BIOTECHNOLOGY
- Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
- (2016) Beth O. Van Emburgh et al. Nature Communications
- Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
- (2015) Thomas Reinert et al. GUT
- Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
- (2014) Alain R Thierry et al. NATURE MEDICINE
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started